SBIO - ALPS Medical Breakthroughs ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
42.54
-0.07 (-0.16%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close42.61
Open42.81
Bid0.00 x 800
Ask0.00 x 1000
Day's Range42.54 - 42.87
52 Week Range30.14 - 43.96
Volume88,493
Avg. Volume63,654
Net Assets210.79M
NAV42.53
PE Ratio (TTM)N/A
Yield0.04%
YTD Daily Total Return0.57%
Beta (5Y Monthly)1.49
Expense Ratio (net)0.50%
Inception Date2014-12-30
  • Best Small-Cap ETFs for Q1 2020
    Investopedia

    Best Small-Cap ETFs for Q1 2020

    Small-cap exchange-traded funds (ETFs) are designed to invest in a basket of stocks whose underlying companies have relatively small market capitalizations. A small-cap company is generally one whose total shares outstanding are considered to have a market value somewhere between $300 million and $2 billion.

  • Best Healthcare ETFs for Q1 2020
    Investopedia

    Best Healthcare ETFs for Q1 2020

    Healthcare exchange-traded funds (ETFs) invest in a basket of stocks of companies that provide medical services, develop medical equipment or drugs, offer medical insurance, or facilitate the provision of healthcare to patients.

  • 4 Sector ETFs That Beat the Market in Q4
    Zacks

    4 Sector ETFs That Beat the Market in Q4

    While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.

  • Biotech Leading in Q4: Best ETFs & Stocks
    Zacks

    Biotech Leading in Q4: Best ETFs & Stocks

    We highlight five biotech ETFs and stocks that are leading the market in Q4.

  • Will Biotech ETFs Excel in Election Year Post a Surge in 2019?
    Zacks

    Will Biotech ETFs Excel in Election Year Post a Surge in 2019?

    Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

  • 5 ETF Areas Up At Least 45% in 2019
    Zacks

    5 ETF Areas Up At Least 45% in 2019

    These ETF areas crushed the S&P 500 in 2019.

  • Beyond Biotech, 5 ETFs Up At Least 10% in Q4
    Zacks

    Beyond Biotech, 5 ETFs Up At Least 10% in Q4

    Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.

  • Why Biotech ETFs are Surging to New Highs
    Zacks

    Why Biotech ETFs are Surging to New Highs

    increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

  • Biotech ETFs Hit New Highs on Deal Activities
    Zacks

    Biotech ETFs Hit New Highs on Deal Activities

    Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

  • A Guide to Biotech ETF Investing
    Zacks

    A Guide to Biotech ETF Investing

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

  • Russell 2000 Hits New 1-Year High: 5 Best-Performing ETFs
    Zacks

    Russell 2000 Hits New 1-Year High: 5 Best-Performing ETFs

    Small caps started to show their momentum and are trying to catch up with the large cap peers. The Russell 2000 Index hit a new 52-week high.

  • 5 ETFs That Deserve Special Thanks in 2019
    Zacks

    5 ETFs That Deserve Special Thanks in 2019

    These ETFs deserve special thanks and attention going into the New Year.

  • Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD
    Zacks

    Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

    Healthcare bounced back with an outperformance starting the fourth quarter.

  • The Zacks Analyst Blog Highlights: SEA, SBIO, WOOD, CRAK and FTXL
    Zacks

    The Zacks Analyst Blog Highlights: SEA, SBIO, WOOD, CRAK and FTXL

    The Zacks Analyst Blog Highlights: SEA, SBIO, WOOD, CRAK and FTXL

  • 5 Best Sector ETFs of October With Double-Digit Returns
    Zacks

    5 Best Sector ETFs of October With Double-Digit Returns

    October has been kind to the U.S. stock market thanks to U.S.-China trade progress, better-than-expected corporate earnings and a third Fed rate cut.

  • Healthcare ETFs Win in October: Here's Why
    Zacks

    Healthcare ETFs Win in October: Here's Why

    The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

  • Navigating The Healthcare Industry: Science Fiction Turns to Reality
    Zacks

    Navigating The Healthcare Industry: Science Fiction Turns to Reality

    Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!

  • Biotech ETFs Surge on a Flurry of Positive News
    Zacks

    Biotech ETFs Surge on a Flurry of Positive News

    The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

  • ETF Trends

    ACADIA Pharmaceuticals Help Lift Biotech ETFs

    While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS: ...

  • Top-Performing Biotech ETFs YTD
    Zacks

    Top-Performing Biotech ETFs YTD

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.

  • 7 Biotech ETFs That Should Remain Healthy
    InvestorPlace

    7 Biotech ETFs That Should Remain Healthy

    The healthcare sector is struggling this year. In 2018, the group was the best-performing sector in the S&P 500. This year, it's the worst. The Dow Jones U.S. Health Care Index is up just 10.20% year-to-date, but there are some pockets of strength and potential growth opportunities in the S&P 500's third-largest sector weight.Source: Shutterstock Biotechnology is one of those groups. Some biotech ETFs aren't setting the market ablaze this year, but broadly speaking, biotech ETFs are outperforming diversified healthcare funds. For example, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), the largest biotech ETF by assets, is up almost 10% year-to-date.The current market environment, marked by lower interest rates and escalating trade tensions, could actually favor biotech ETFs due to the groups' emphasis on the U.S. economy. Plus, the broader healthcare sector looks inexpensive relative to other defensive sectors.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Health care, the worst-performing sector this year, trades at 15 times forward earnings, below the 17 times multiple on the S&P 500. By comparison, staples, utilities and REITs trade closer to 20 times earnings," reports CNBC. * 10 Generation Z Stocks to Buy Long Here are some biotech ETFs to consider right here, right now. SPDR S&P Biotech ETF (XBI)Expense ratio: 0.35% per year, or $35 on a $10,000 investment.The SPDR S&P Biotech ETF (NYSEARCA:XBI) is home to $4.15 billion in assets under management, making it one of the largest biotech ETFs, but XBI's size is not why it is being highlighted here. For active traders, XBI is worth a look right now because during the week starting Monday, Aug 5, half of XBI's 119 holdings report earnings, so there are plenty of catalysts that could move this fund in the near term.XBI is an equal weight ETF and as such tilts toward smaller biotech names as highlighted by an average market value of $10.6 billion for the fund's components, putting it in mid-cap territory. XBI status as an imminent earnings play is relevant because FactSet expects second-quarter earnings for the healthcare sector to rise an average of 2.1%, the second-best growth rate among the 11 S&P 500 sectors.What could be a challenge for XBI and other biotech ETFs over the near term is campaign-trail chatter about drug prices (many XBI components are considered pharmaceuticals makers), but in the fund's corner are decent valuations and status of many of its holdings as credible takeover targets. Invesco Dynamic Biotechnology & Genome ETF (PBE)Source: Shutterstock Expense ratio: 0.59%The Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is an ideal biotech ETF for investors looking for a smart beta approach to the space. PBE, which turned 14 years old in June, tracks the Dynamic Biotech & Genome Intellidex Index.That benchmark "is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value," according to Invesco. * 7 A-Rated Stocks Under $10 Smart beta is not always perfect, but its applications in the biotech ETF space are notable. Over the past three years, PBE has beaten a major cap-weighted index of biotechnology stocks by a margin of better than 3-to-1 with only slightly higher volatility. ALPS Medical Breakthroughs ETF (SBIO)Source: Shutterstock Expense ratio: 0.50% per yearThe ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) has long been a unique alternative to traditional biotech ETFs and with its emphasis on small-cap and smaller mid-cap stocks, SBIO can also be an alternative for risk-tolerant investors looking to replace standard small equity exposure.In addition to capping components' market values at the time of entry at $5 billion, SBIO's underlying index requires that those companies have at least one drug or therapy in Phase II or III Food and Drug Administration (FDA) trials. So while there can be no guarantees that SBIO holdings will become the next Amgen or Gilead, at least investors know the fund is not chock full of financially flimsy fly-by-night biotech stocks.And speaking of finances, SBIO components must have enough cash to survive at least two years to be included in the fund. That's a stiffer requirement than is found on standard small-cap ETFs, perhaps explaining why over the past three years SBIO is not just one of the best biotech ETFs, but one of the best small-cap funds, too. Global X Genomics & Biotechnology ETF (GNOM) Source: Shutterstock Expense ratio: 0.68%Having debuted in April, the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) is one of the newest biotech ETFs on the market. Rookie status aside, this Global X fund addresses a compelling, fast-growing corner of the healthcare market."There are several segments within the genomics field that stand to benefit from falling genetic testing costs, the rise of precision medicine ever-increasing amounts of genetic data, and other trends fueling genomics' disruption of health care," according to Global X research. * 10 High-Yield Monthly Dividend Stocks to Buy As an industry, genomics is not nearly as old some other healthcare groups, but the upside of that is that the industry offers plenty of growth potential via areas such as gene sequencing, gene editing, computational genomics and genetic diagnostics and more. Home to 40 stocks, a decent-sized lineup for a niche ETF like this, GNOM touches many of the exciting corners of the genomics investment thesis. ROBO Global Healthcare Technology and Innovation ETF (HTEC)Source: Shutterstock Expense ratio: 0.68%Having debuted in late June, the ROBO Global Healthcare Technology and Innovation ETF (NYSEARCA:HTEC) is the newest of biotech ETFs highlighted here and to be clear, it is not a dedicated biotech ETF. Rather, HTEC is designed as a play on the themes of healthcare disruption and innovation, but that can and should some biotechnology exposure. HTEC targets the ROBO Global Healthcare Technology and Innovation Index. "We anticipate that this technology revolution should profoundly transform the healthcare industry, offering a potential opportunity to investors over the next decade," according to ROBO Global. "It is about shifting the model from caring for the sick to one of prevention, prediction and eradication of diseases. It is about enhancing physicians' accuracy and therapies' efficacy. Finally, it is about lowering costs. The expected result: longer, healthier lifespans."HTEC has a broad lineup at 85 components, but a good percentage of those names dwell in the genomics and pharmaceuticals arenas, giving this fund some credibility as a biotech ETF. Importantly, the intersection of healthcare and artificial intelligence (AI), one of HTEC's points of emphasis, is real and growing."A.I. in health care could balloon to a $6.6 billion industry by 2021 form the $600 million back in 2014. A.I. funding has almost doubled to $2.3 billion in 2018, compared to $1.2 billion in 2017," according to ETF Trends. ARK Genomic Revolution Multi-Sector ETF (ARKG)Source: Shutterstock Expense ratio: 0.75%For those looking for active management with their genomics investments, an advisable strategy in many instances, the ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is one of the best funds to consider. "Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business," according to ARK Investment Management.ARKG usually holds 30 to 50 stocks, but the fund typically spans into a half dozen fast-growing corners of the biotech space, including CRISPIR, bioinformatics, molecular diagnostics and more. * 10 Small-Cap Stocks to Buy Before They Grow Up Past performance is never a guarantee of future returns, but the ARK team are excellent stock pickers. Over the past three years, ARKG is beating the largest biotech ETF by a margin of more than 8-to-1. Invesco S&P SmallCap Health Care ETF (PSCH)Source: Shutterstock Expense ratio: 0.29%The Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH) is an almost biotech ETF. "Almost" because as its name implies, it's a diverse healthcare ETF, but when small-cap and healthcare stocks come together, biotechnology is usually involved.PSCH confirms as much as nearly 29% of its holdings, its largest industry weight, are biotechnology names. Earlier, I mentioned that healthcare stocks are trading at attractive valuations, but that's not the case with PSCH, which trades at 34x earnings. However, for investors that can stomach the added volatility, PSCH is worth the lofty multiples.Over the past three years, this biotech ETF was 320 basis points more volatile than the S&P SmallCap 600 Index, but the Invesco funds outperformed that index by nearly 2-to-1.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Generation Z Stocks to Buy Long * 5 Growth Stocks to Buy After the Rate Cut * 5 Dependable Dividend ETFs to Invest In The post 7 Biotech ETFs That Should Remain Healthy appeared first on InvestorPlace.

  • Why These Innovative Biotech ETFs Soaring
    Zacks

    Why These Innovative Biotech ETFs Soaring

    Strong M&A activity has sent shares of many small, innovative biotech companies surging

  • Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
    Zacks

    Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

    Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.

  • ETF Trends

    Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal

    Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY) in a $10.6 billion deal to bolster its portfolio of cancer fighting ...

  • Markets & ETFs Digest Trade Spat: Is It a Dead-Cat-Bounce?
    Zacks

    Markets & ETFs Digest Trade Spat: Is It a Dead-Cat-Bounce?

    Though markets rallied probably on the undervalued status and a still-steady US economy, rising recessionary fears and full-scale trade war risks should brighten the appeal of safer ETFs.